Biogen
NEWS
The new year began with a fairly low level of clinical trial news. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 15, 2020.
A Biogen corporate conference held in February at the Boston Marriott Long Wharf Hotel was initially traced to about 100 cases of COVID-19 that spread across the country. That number has grown exponentially.
The consumer’s group Public Citizen demanded the Office of the Inspector General (OIG) for the U.S. Department of Health and Human (HHS) conduct an investigation.
Sage and Biogen forged the deal to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.
With the opinions that were expressed by the advisory committee, along with the data presented, the FDA will continue onward with its review process. It is expected to determine whether to approve the aducanumab Biologics License Application by March 7, 2021.
Biogen and Tokyo-based development partner Eisai are embroiled in controversy surrounding their investigational Alzheimer’s drug, aducanumab.
Additional findings from Biogen’s Phase II LILAC study, announced today, show the company’s lupus drug candidate BIIB059 is superior to placebo for reducing joint disease activity in patients with systemic lupus erythematosus.
Biogen originally announced the initiation of its Phase II clinical trial, AFFINITY, designed to evaluate opicinumab back in 2017. The drug was being examined as an investigational add-on therapy for patients with relapsing MS.
JOBS
IN THE PRESS